Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus Deferred Cytoreductive Nephrectomy with Ipilimumab/Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
KCT0010857Phase 3Not yet recruiting
- Sponsor
- The Korean Urological Oncology Society
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ipilimumab, nivolumab in clear cell renal cell carcinoma (ccRCC), sponsored by The Korean Urological Oncology Society. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on KCT0010857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010857.